Stocks › PTGX
Protagonist Therapeutics, Inc (PTGX) stock analysis
WEAK BUY 31% confidence · analysed Nov 4, 2026
On Nov 4, 2026, our model rated Protagonist Therapeutics, Inc (PTGX) WEAK BUY with 31% confidence at a price of $140.24. That means the signals lean positive, but they are mixed, so conviction is low.
Technical picture
The 14-day RSI is 56, showing healthy upward momentum without being stretched.
MACD is above its signal line, a sign that short-term momentum is turning up.
The price has slipped below its 50-day moving average but is still above the 200-day: a pullback inside a longer-term uptrend.
Volume is about normal (1.0x the 20-day average).
Trend structure and money flow
Market structure: bullish structure intact, no fresh break.
The most recent swing high is $160.81 and the swing low is $77.00; traders often treat these as resistance and support.
Price is sitting in a bullish order block, a zone where large buyers stepped in before.
Fundamentals
The company reports a profit margin of 29.4% and revenue growth of +3749.2%.
In its latest quarter it earned $2.29 per share, which beat the $1.94 analysts expected, with revenue +3749.2% year over year.
Wall Street's average rating is 1.2 on a 1 (strong buy) to 5 (sell) scale, roughly a "strong buy", with an average price target of $178.57.
The next earnings report is expected around Nov 5, 2026; prices often move sharply around earnings.
Trade plan from the model
The model's long / bullish plan uses an entry near $140.24, a target of $152.43 (+8.7%) and a stop-loss at $129.69 (-7.5%).
That is a reward-to-risk ratio of about 1.2 to 1: the potential gain is not much bigger than the loss, so the setup is marginal.
The plan has a time limit: reassess by Nov 4, 2026 whatever the price does.
The model's one-paragraph read
Leans BUY — composite score +0.31 (WEAK BUY). Technicals: RSI 56.05, MACD bullish, price below SMA50. Fundamentals: margin 29.4%, revenue growth 3749.2%. Financial results: YoY revenue +3749.2%, last EPS surprise +18.0%, next earnings 2026-11-05. Smart Money Concepts: bullish structure intact, no fresh break, price retesting a bullish order block. FinGPT news read: positive. Suggested levels: entry $140.24, target $152.43, stop-loss $129.69, exit by 2026-11-04 (exit before next earnings (2026-11-05) -- this signal doesn't price in that report).
Past ratings for PTGX
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Nov 4, 2026 | WEAK BUY | 31% | $140.24 | — |
"Move since" compares each call's price with the latest analysed price.
Frequently asked questions
Is PTGX a buy right now?
As of Nov 4, 2026, our automated model rates Protagonist Therapeutics, Inc (PTGX) WEAK BUY with 31% confidence: the signals lean positive, but they are mixed, so conviction is low. This is a model output for education, not personal investment advice.
What is the price target for PTGX?
The model's most recent plan targets $152.43 with a stop-loss at $129.69, from an entry near $140.24.
When does Protagonist Therapeutics, Inc report earnings next?
The next earnings report is expected around Nov 5, 2026.
What does a WEAK BUY rating mean?
A WEAK BUY rating means the signals lean positive, but they are mixed, so conviction is low.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.